collection
MENU ▼
Read by QxMD icon Read
search

LUNG

shared collection
275 papers 25 to 100 followers
https://www.readbyqxmd.com/read/28603066/differential-gene-expression-profiles-according-to-the-iaslc-ats-ers-histopathological-classification-in-lung-adenocarcinoma-subtypes
#1
Camilo Molina-Romero, Claudia Rangel-Escareño, Alette Ortega-Gómez, Gerardo J Alanis-Funes, Alejandro Aviles-Salas, Federico Avila-Moreno, Gabriela E Mercado, Andres F Cardona, Alfredo Hidalgo-Miranda, Oscar Arrieta
The current lung cancer classification from the Association for the Study of Lung Cancer (IASLC) / the American Thoracic Society (ATS)/ the European Respiratory Society (ERS) has considerably changed the pathologic diagnosis of lung invasive adenocarcinoma, identifying disease subtypes with substantial implications for medical practice, such as clinical, radiological, molecular and prognostic differences. We analyzed the differences in the genetic expression of adenocarcinoma subtypes according to the new classification...
June 8, 2017: Human Pathology
https://www.readbyqxmd.com/read/28613913/hypersensitivity-pneumonitis-a-perspective-from-members-of-the-pulmonary-pathology-society
#2
Ross Miller, Timothy Craig Allen, Roberto J Barrios, Mary Beth Beasley, Louise Burke, Philip T Cagle, Vera Luiza Capelozzi, Yimin Ge, Lida P Hariri, Keith M Kerr, Andras Khoor, Brandon T Larsen, Eugene J Mark, Osamu Matsubara, Mitra Mehrad, Mari Mino-Kenudson, Kirtee Raparia, Anja Christiane Roden, Prudence Russell, Frank Schneider, Lynette M Sholl, Maxwell Lawrence Smith
CONTEXT: - Hypersensitivity pneumonitis (HP) is a lung disease that develops in susceptible individuals after inhalational exposure to an organic antigen or chemical compound. Pathogenesis is attributed to a combination of type III (immune complex-mediated) and type IV (delayed) hypersensitivity reactions to the inciting agent. OBJECTIVE: - To provide an overview of the current status of the medical literature regarding hypersensitivity pneumonitis. DATA SOURCES: - A literature search was performed using PubMed and Google search engines...
June 14, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28609002/analytic-inquiry-molecular-testing-in-lung-cancer
#3
Maureen F Zakowski
Non-small cell lung cancer is a different disease from what it was a decade ago. The last 10 years were based on remarkable advances in the understanding of key genetic alterations that function as oncogenic drivers and serve as therapeutic targets, thereby defining new molecular subsets. These changes have had an impact on clinical care, patient outcomes, and pathologic diagnosis and present new challenges in the approach of the cytopathologist to this still deadly disease. To meet these new challenges and appropriately train the next generation of cytopathologists, the complex molecular background underlying this disease and the implications that cytologic and histologic diagnoses have on treatment must be understood...
June 2017: Cancer
https://www.readbyqxmd.com/read/28579481/scientific-advances-in-thoracic-oncology-2016
#4
REVIEW
Ross A Soo, Emily Ca Stone, K Michael Cummings, James R Jett, John K Field, Harry Jm Groen, James L Mulshine, Yasushi Yatabe, Lukas Bubendorf, Sanja Dacic, Ramon Rami-Porta, Frank C Detterbeck, Eric Lim, Hisao Asamura, Jessica Donington, Heather A Wakelee, Yi Long Wu, Kristin Higgins, Suresh Senan, Benjamin Solomon, Dong-Wan Kim, Melissa Johnson, James Ch Yang, Lecia V Sequist, Alice T Shaw, Myung-Ju Ahn, Daniel B Costa, Jyoti D Patel, Leora Horn, Scott Gettinger, Solange Peters, Murry W Wynes, Corinne Faivre-Finn, Charles M Rudin, Anne Tsao, Paul Baas, Ronan J Kelly, Natasha B Leighl, Giorgio V Scagliotti, David R Gandara, Fred R Hirsch, David R Spigel
Lung cancer care is rapidly changing with advances in genomic testing, the development of next-generation targeted kinase inhibitors, and the continued broad study of immunotherapy in new settings and potential combinations. The IASLC and the Journal of Thoracic Oncology publish this annual update to help readers keep pace with these important developments. Experts in thoracic cancer and care provide focused updates across multiple areas including prevention and early detection, molecular diagnostics, pathology and staging, surgery, adjuvant therapy, radiotherapy, molecular targeted therapy, and immunotherapy for non-small cell lung cancer, small cell lung cancer, and mesothelioma...
May 27, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28529900/immunotherapy-and-radiation-therapy-for-operable-early-stage-and-locally-advanced-non-small-cell-lung-cancer
#5
REVIEW
Neil K Taunk, Andreas Rimner, Melissa Culligan, Joseph S Friedberg, Julie Brahmer, Jamie Chaft
Non-small cell lung cancer (NSCLC) is the most common cause of cancer mortality. Although a significant proportion of patients can be cured with surgery, with or without adjuvant or neoadjuvant chemotherapy and radiation, a significant proportion of patients will fail, particularly distantly. Over fifty percent of patients present with stage IV disease. There are multiple forms of immunotherapy available including T-cell transfer, cytokine therapy, and oncolytic viruses. Checkpoint inhibitors have shown tremendous activity in NSCLC and are currently under intense study given promising data on response...
April 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28574849/strategies-targeting-angiogenesis-in-advanced-non-small-cell-lung-cancer
#6
REVIEW
Jun Wang, Jianpeng Chen, Yan Guo, Baocheng Wang, Huili Chu
Tumor angiogenesis is a frequent event in the development and progression of non-small cell lung cancer (NSCLC) and has been identified as a promising therapeutic target. The vascular endothelial growth factor (VEGF) family and other angiogenic factors, including fibroblast growth factor and platelet-derived growth factor, promote the growth of newly formed vessels from preexisting vessels and change the tumor microenvironment. To date, two antiangiogenic monoclonal antibodies, bevacizumab and ramucirumab, which target VEGF-A and its receptor VEGF receptor-2, respectively, have been approved for the treatment of locally advanced or metastatic NSCLC when added to first-line standard chemotherapy...
May 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28529897/uncovering-the-immune-tumor-microenvironment-in-non-small-cell-lung-cancer-to-understand-response-rates-to-checkpoint-blockade-and-radiation
#7
REVIEW
Jonathan E Schoenhals, Steven N Seyedin, Clark Anderson, Eric D Brooks, Yun R Li, Ahmed I Younes, Sharareh Niknam, Ailin Li, Hampartsoum B Barsoumian, Maria Angelica Cortez, James W Welsh
The study of immunology has led to breakthroughs in treating non-small cell lung cancer (NSCLC). The recent approval of an anti-PD1 checkpoint drug for NSCLC has generated much interest in novel combination therapies that might provide further benefit for patients. However, a better understanding of which combinations may (or may not) work in NSCLC requires understanding the lung immune microenvironment under homeostatic conditions and the changes in that microenvironment in the setting of cancer progression and with radiotherapy...
April 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28529902/current-state-of-immunotherapy-for-non-small-cell-lung-cancer
#8
REVIEW
Jyoti Malhotra, Salma K Jabbour, Joseph Aisner
Lung cancer is the leading cause of cancer mortality and non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancers. Platinum-based doublet chemotherapy is the standard first-line treatment for metastatic NSCLC when genomic testing reveals no targetable alteration such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) or ROS1 translocation/re-arrangements. But, chemotherapy produces response rates ranging only between 15-30%. For patients whose disease progresses on first-line chemotherapy, second-line therapy historically consists of taxane-based salvage chemotherapy with a response rate of less than 25%...
April 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28529906/cons-the-confusing-mucinous-adenocarcinoma-classification
#9
EDITORIAL
Helmut H Popper
No abstract text is available yet for this article.
April 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28529905/pros-the-present-classification-of-mucinous-adenocarcinomas-of-the-lung
#10
EDITORIAL
Sanja Dacic
No abstract text is available yet for this article.
April 2017: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28543219/prognostic-value-of-visceral-pleural-invasion-in-non-small-cell-lung-cancer-a-propensity-score-matching-study-based-on-the-seer-registry
#11
Xiaodong Yang, Fenghao Sun, Li Chen, Mengkun Shi, Yu Shi, Zongwu Lin, Mingxiang Feng, Cheng Zhan, Wei Jiang, Qun Wang
BACKGROUND AND OBJECTIVES: Visceral pleural invasion (VPI) is considered a poor prognostic factor in non-small cell lung cancer (NSCLC). We aimed to analyze the effect of VPI on cancer-specific survival, using propensity score matching (PSM) based on the Surveillance, Epidemiology, and End Results database. METHODS: We identified 9901 patients with T1-2N0-2M0 who received segmentectomy, lobectomy, or pneumonectomy. Ten covariates were included in PSM. The effect of VPI on survival was assessed, stratified by nodal status and tumor size...
May 22, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28539214/validation-of-the-eighth-edition-of-the-tnm-staging-system-for-lung-cancer-in-2043-surgically-treated-patients-with-non-small-cell-lung-cancer
#12
Kezhong Chen, Haiqing Chen, Fan Yang, Xizhao Sui, Xiao Li, Jun Wang
PURPOSE: The International Association for the Study of Lung Cancer has proposed a revision of the Tumor, Node, Metastasis (TNM) classification for lung cancer. The purpose of this study is to evaluate the prognostic value of the eighth edition of the TNM staging system in surgically treated patients with non-small-cell lung cancer. METHODS: Data from 2043 consecutive patients with non-small-cell lung cancer who underwent surgical treatment in our single center between January 2006 and September 2015 were collected and analyzed retrospectively...
April 12, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28537805/pathology-of-chronic-hypersensitivity-pneumonitis-what-is-it-what-are-the-diagnostic-criteria-why-do-we-care
#13
Andrew Churg, AnaMaria Bilawich, Joanne L Wright
CONTEXT: - Chronic hypersensitivity pneumonitis (CHP) has emerged from obscurity during the past 15 years and is now recognized as a very common form of fibrosing interstitial pneumonia but one that is frequently misdiagnosed both clinically and on surgical lung biopsy as usual interstitial pneumonia/idiopathic pulmonary fibrosis (UIP/IPF) or fibrotic nonspecific interstitial pneumonia. OBJECTIVE: - To review the pathologic features of CHP. DATA SOURCES: - Clinical, pathology, and radiology literature were used...
May 24, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28467213/interstitial-pneumonia-with-autoimmune-features-value-of-histopathology
#14
Ayodeji Adegunsoye, Justin M Oldham, Eleanor Valenzi, Cathryn Lee, Leah J Witt, Lena Chen, Steven Montner, Jonathan H Chung, Imre Noth, Rekha Vij, Mary E Strek, Aliya N Husain
CONTEXT: - Patients with idiopathic interstitial pneumonia may display evidence of autoimmunity, without meeting criteria for a defined connective tissue disease. A recent European Respiratory Society/American Thoracic Society statement proposed research criteria for interstitial pneumonia with autoimmune features (IPAF), which includes findings from the clinical, serologic, and morphologic domains. OBJECTIVES: - To investigate the importance of histopathologic criteria within the morphologic domain and to report our methodology for identifying these features...
May 3, 2017: Archives of Pathology & Laboratory Medicine
https://www.readbyqxmd.com/read/28523184/pd-1-targeted-immunotherapy-as-first-line-therapy-for-advanced-non-small-cell-lung-cancer-patients
#15
EDITORIAL
Arik Bernard Schulze, Lars Henning Schmidt
No abstract text is available yet for this article.
April 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28523187/non-small-cell-lung-cancer-genomics-around-the-globe-focus-on-ethnicity
#16
COMMENT
Luiz H Araujo, David P Carbone
No abstract text is available yet for this article.
April 2017: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/28474862/case-of-sclerosing-pneumocytoma-combined-with-a-typical-carcinoid-and-pulmonary-adenocarcinoma-in-different-lobes
#17
Hwa Jin Cho, Ji Hyeon Lee, Geon Kook Lee, Eun Kyung Hong, Hyae Young Kim
We report the first case of a 62-year-old man with a sclerosing pneumocytoma (SP) combined with a typical carcinoid (TC) and pulmonary adenocarcinoma in different lung lobes. Computed tomography revealed two nodules. The radiological diagnosis was primary lung cancer and a metastatic nodule; however, no enlarged lymph nodes were observed. Histological and immunohistochemical analyses defined the 1.7 cm nodule in the right upper lobe as adenocarcinoma and the 1.3 cm nodule in the left lower lobe as SP combined with TC...
May 5, 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/21303969/lung-cancer-new-biological-insights-and-recent-therapeutic-advances
#18
Suresh S Ramalingam, Taofeek K Owonikoko, Fadlo R Khuri
Approximately 1.6 million new cases of lung cancer are diagnosed each year throughout the world. In many countries, the mortality related to lung cancer continues to rise. The outcomes for patients with all stages of lung cancer have improved in recent years. The use of systemic therapy in conjunction with local therapy has led to improved cure rates in both resectable and unresectable patient groups. For patients with advanced stage disease, modest but real improvements in overall survival and quality of life have been achieved with systemic chemotherapy...
March 2011: CA: a Cancer Journal for Clinicians
https://www.readbyqxmd.com/read/28416123/immune-checkpoint-inhibitors-for-patients-with-advanced-non-small-cell-lung-cancer-a%C3%A2-systematic-review
#19
REVIEW
Peter M Ellis, Emily T Vella, Yee C Ung
Second-line treatment options are limited for patients with advanced non-small-cell lung cancer (NSCLC). Standard therapy includes the cytotoxic agents docetaxel and pemetrexed, and the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors erlotinib and gefitinib. Immune checkpoint inhibitors are a new class of treatment that have shown durable overall radiologic response rates and have been well tolerated. The objective of this systematic review was to investigate the efficacy of immune checkpoint inhibitors compared with other chemotherapies in patients with advanced NSCLC...
February 16, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/28446601/diffuse-parenchymal-lung-disease
#20
REVIEW
Sara Tomassetti, Claudia Ravaglia, Venerino Poletti
Between September 2015 and August 2016 there were >1500 publications in the field of diffuse parenchymal lung diseases (DPLDs). For the Clinical Year in Review session at the European Respiratory Society Congress that was held in London, UK, in September 2016, we selected only five articles. This selection, made from the enormous number of published papers, does not include all the relevant studies that will significantly impact our knowledge in the field of DPLDs in the near future. This review article provides our personal view on the following topics: early diagnosis of idiopathic pulmonary fibrosis, current knowledge on the multidisciplinary team diagnosis of DPLDs and the diagnostic role of transbronchial cryobiopsy in this diagnostic setting, insights on the new entity of interstitial pneumonia with autoimmune features, and new therapeutic approaches for scleroderma-related interstitial lung disease...
June 30, 2017: European Respiratory Review: An Official Journal of the European Respiratory Society
label_collection
label_collection
6334
1
2
2017-05-01 10:42:04
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"